Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis - PubMed (original) (raw)
Review
. 2005 Dec;46(12):2531-58.
doi: 10.1194/jlr.R500011-JLR200. Epub 2005 Oct 5.
Affiliations
- PMID: 16207929
- DOI: 10.1194/jlr.R500011-JLR200
Free article
Review
Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis
Stephen G Young et al. J Lipid Res. 2005 Dec.
Free article
Abstract
Prelamin A undergoes multistep processing to yield lamin A, a structural protein of the nuclear lamina. Prelamin A terminates with a CAAX motif, which triggers farnesylation of a C-terminal cysteine (the C of the CAAX motif), endoproteolytic release of the last three amino acids (the AAX), and methylation of the newly exposed farnesylcysteine residue. In addition, prelamin A is cleaved a second time, releasing 15 more residues from the C terminus (including the farnesylcysteine methyl ester), generating mature lamin A. This second cleavage step is carried out by an endoplasmic reticulum membrane protease, ZMPSTE24. Interest in the posttranslational processing of prelamin A has increased with the recognition that certain progeroid syndromes can be caused by mutations that lead to an accumulation of farnesyl-prelamin A. Recently, we showed that a key cellular phenotype of these progeroid disorders, misshapen cell nuclei, can be ameliorated by inhibitors of protein farnesylation, suggesting a potential strategy for treating these diseases. In this article, we review the posttranslational processing of prelamin A, describe several mouse models for progeroid syndromes, explain the mutations underlying several human progeroid syndromes, and summarize recent data showing that misshapen nuclei can be ameliorated by treating cells with protein farnesyltransferase inhibitors.
Similar articles
- Prelamin A farnesylation and progeroid syndromes.
Young SG, Meta M, Yang SH, Fong LG. Young SG, et al. J Biol Chem. 2006 Dec 29;281(52):39741-5. doi: 10.1074/jbc.R600033200. Epub 2006 Nov 7. J Biol Chem. 2006. PMID: 17090536 Review. - Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI, Yang SH, Qiao X, Beigneux AP, Gelb MH, Moulson CL, Miner JH, Young SG, Fong LG. Toth JI, et al. Proc Natl Acad Sci U S A. 2005 Sep 6;102(36):12873-8. doi: 10.1073/pnas.0505767102. Epub 2005 Aug 29. Proc Natl Acad Sci U S A. 2005. PMID: 16129834 Free PMC article. - Inhibiting farnesylation reverses the nuclear morphology defect in a HeLa cell model for Hutchinson-Gilford progeria syndrome.
Mallampalli MP, Huyer G, Bendale P, Gelb MH, Michaelis S. Mallampalli MP, et al. Proc Natl Acad Sci U S A. 2005 Oct 4;102(40):14416-21. doi: 10.1073/pnas.0503712102. Epub 2005 Sep 26. Proc Natl Acad Sci U S A. 2005. PMID: 16186497 Free PMC article. - The posttranslational processing of prelamin A and disease.
Davies BS, Fong LG, Yang SH, Coffinier C, Young SG. Davies BS, et al. Annu Rev Genomics Hum Genet. 2009;10:153-74. doi: 10.1146/annurev-genom-082908-150150. Annu Rev Genomics Hum Genet. 2009. PMID: 19453251 Free PMC article. Review. - Blocking protein farnesyltransferase improves nuclear blebbing in mouse fibroblasts with a targeted Hutchinson-Gilford progeria syndrome mutation.
Yang SH, Bergo MO, Toth JI, Qiao X, Hu Y, Sandoval S, Meta M, Bendale P, Gelb MH, Young SG, Fong LG. Yang SH, et al. Proc Natl Acad Sci U S A. 2005 Jul 19;102(29):10291-6. doi: 10.1073/pnas.0504641102. Epub 2005 Jul 12. Proc Natl Acad Sci U S A. 2005. PMID: 16014412 Free PMC article.
Cited by
- Targeting isoprenylcysteine methylation ameliorates disease in a mouse model of progeria.
Ibrahim MX, Sayin VI, Akula MK, Liu M, Fong LG, Young SG, Bergo MO. Ibrahim MX, et al. Science. 2013 Jun 14;340(6138):1330-3. doi: 10.1126/science.1238880. Epub 2013 May 16. Science. 2013. PMID: 23686339 Free PMC article. - Small-molecule inhibitors of the Rce1p CaaX protease.
Manandhar SP, Hildebrandt ER, Schmidt WK. Manandhar SP, et al. J Biomol Screen. 2007 Oct;12(7):983-93. doi: 10.1177/1087057107307226. J Biomol Screen. 2007. PMID: 17942791 Free PMC article. - Good news in the nuclear envelope: loss of lamin A might be a gain.
Scaffidi P, Misteli T. Scaffidi P, et al. J Clin Invest. 2006 Mar;116(3):632-4. doi: 10.1172/JCI27820. J Clin Invest. 2006. PMID: 16511598 Free PMC article. Review. - Inhibition of the CaaX proteases Rce1p and Ste24p by peptidyl (acyloxy)methyl ketones.
Porter SB, Hildebrandt ER, Breevoort SR, Mokry DZ, Dore TM, Schmidt WK. Porter SB, et al. Biochim Biophys Acta. 2007 Jun;1773(6):853-62. doi: 10.1016/j.bbamcr.2007.03.004. Epub 2007 Mar 20. Biochim Biophys Acta. 2007. PMID: 17467817 Free PMC article. - Assessing the efficacy of protein farnesyltransferase inhibitors in mouse models of progeria.
Yang SH, Chang SY, Andres DA, Spielmann HP, Young SG, Fong LG. Yang SH, et al. J Lipid Res. 2010 Feb;51(2):400-5. doi: 10.1194/jlr.M002808. Epub 2009 Oct 26. J Lipid Res. 2010. PMID: 19965595 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases